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Sources of human urinary epinephrine. The kidney is a likely source for
some urinary epinephrine (E) since adrenalectomized animals and hu-
mans continue to excrete urinary E and the human kidney contains E
synthesizing enzymes. We studied subjects during an intravenous infusion
of 3H-E to determine the fraction of urinary E derived from the kidney.
Eight normal subjects (CON) and 5 older, heavier hypertensives (OHH)
ate a light breakfast along with ascorbic acid supplementation and had
intravenous and arterial lines placed. They received an infusion of 3H-E
and had an oral water load. During the final hour of 3H-E infusion, urine
and arterial blood samples were collected for 3H-E and E levels. After the
3H-E infusion was abruptly discontinued, arterial blood samples were
collected to measure 3H-E kinetics. The total body clearance of 3H-E was
about 2,500 mI/mm from plasma and clearance of 3H-E to urine was about
170 mI/mm. CON had plasma E levels of 43 4 pg/mI. Their predicted
rate of clearance of E from plasma to urine of 7,471 865 pg/mm was less
than (P = 0.018) the actual urinary E excretion of 15,037 2,625 pg/mm.
Thus, 43 9% of urinary E in CON was apparently derived from renal
sources and not filtered from blood. Among OHH 85 4% of urinary E
was derived from the kidney, significantly (P < 0.01) different from CON.
The OHH also produced much more urinary E than predicted from
plasma 3H-E clearance into urine (P = 0.03). A major fraction of urinary
E is not filtered from the blood stream but is apparently derived from the
kidney. A small fraction of urinary E may be derived from E stored in
nerve endings along with norepinephrine, but this probably represents less
than 2% of urinary E. Renal cleavage of E sulfate into E may be another
potential source of urinary E. Some, and perhaps most, urinary E not
filtered from the bloodstream is derived from renal N-methylation of
norepinephrine as the human kidney has two enzymes capable of convert-
ing norepinephrine to E. In conclusion, a major portion of urinary E is
derived from the kidney and not filtered from the bloodstream. This is an
important factor in the interpretation of urine E levels. Renal E could
alter renal blood flow, electrolyte reabsorption, and renin release prior to
excretion into urine.
Rat [1, 21 and human kidney [3] can synthesize epinephrine (E)
in vitro. The kidney contains two N-methyltransferases that can
convert norepinephrine to E [4]. One of these enzymes is phe-
nylelhanolaminc-N-mcthyltransferase, the enzyme which syrithe-
sizes E in the adrenal. PNMT is located in the renal glomeruli and
tubules where urine is formed. Epinephrine sulfate (E-S04) is
excreted by the kidney and renal sulfatase could convert E-S04 to
E [5].
Epinephrine regulates many renal junctions. The kidney has a,
a7, p, and , adrenergic receptors that regulate renin release,
vascular tone, and sodium absorption [6]. Epinephrine infusions
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too low to alter blood pressure increase renal vascular resistance
and renin release, and decrease sodium, potassium and chloride
levels in urine [7]. Although the kidney can make E, the fraction
of urinary E made by the kidney has not been measured. Several
studies suggest that the fraction of urine E derived from nonad-
renal sources is substantial. Adrenal medullectomy failed to
decrease rat urinary E levels [8]. In another study, urinary E levels
in the rat failed to decrease after removal of the adrenal medullae
and bilateral renal denervation [4]. Bilaterally adrenalectomized
humans are reported to have normal urinary E levels [9]. We
carried out a preliminary study of three subjects that suggested
that urinary E may not simply be filtered from the bloodstream
[31. Since the kidney seems a likely source for urinary E not
derived from the adrenal, we measured the clearance of tritiated
epinephrine (3H-E) into urine and actual urinary E excretion to
estimate the amount of urinary E of renal origin in normal
subjects and in a group of older, heavier hypertensives.
Methods
Subjects for the study were normal volunteers (CON) or
patients who were older, heavier, and who gave a history of
uncomplicated essential hypertension (OHH). Subjects first pro-
vided written informed consent for the study and then had a
medical history, physical examination, electrocardiogram, com-
plete blood count, and serum chemistries performed. Subjects
were excluded if they had significant concomitant disease. Screen-
ing tests were normal in all subjects except for some who had
elevated cholesterol, triglycerides, or left ventricular hypertrophy
on electrocardiogram. The subjects took no medication for two
weeks prior to the study and had no alcohol, tobacco, or caffeine
on the day of the study. On the morning of the study, subjects
were admitted to the Clinical Research Center and had a break-
fast of a bread roll, a pat of margarine, a piece of fruit, a caffeine
free beverage and took one gram of ascorbic acid. They had an
intravenous line placed for 3H-E administration and a radial
artery catheter placed for blood sampling. The subjects received a
water load of 1 liter followed by 250 ml per half-hour to increase
urine flow.
lI-E with a specific activity of 50 Ci/mrnol was sterilized by
passage through a Millipore filter and tested for sterility and
pyrogenieily. The 3H-E was diluted in 250 ml of 5% dextrose with
50 mg ascorbic acid to serve as an antioxidant. The H-E infusion
was begun at 120 j.rCi/hr for 10 minutes and then 60 pCi/hr for 170
minutes. Prior to the last hour of the infusion subjects voided and
that urine was discarded. Throughout the final hour of the
infusion, arterial blood samples were collected for 3H-E and E
levels. The subjects voided at the end of the final hour of infusion
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Table 1. Subject characteristics (mean SEM)
CON OHH P<
N 8 5
Age
Ponderosity kg/si2
32±3
24.6 0.5
59±5
29.9 0.8
Systolic BP mm Hg 120 2 156 10
Diastolic BP mm Hg 75 1 90 2
Triglycerides mg% 148 36 290 53 0.05
Heart rate 69 3 66 2 NS
Creatinine mg% 0.9 0.05 1.2 0.1 NS
and the urine volume was measured and an aliquot frozen. The
3H-E infusion was abruptly stopped and arterial blood samples
were collected at 0.5, 1, 2, 4, 8, and 16 minutes after termination
of the infusion.
Plasma E levels increase in response to stress and hypoglyce-
mia. In order to maintain constant plasma E levels, the subjects
were fed a breakfast with complex carbohydrates and were kept in
a single room on the Clinical Research Center without distrac-
tions. They had vascular catheters inserted three hours prior to
blood and urine sampling and they remained supine and resting
during the 3H-E infusion.
Assays
3H-E was isolated from 1 ml samples of plasma and urine and
0.1 ml of infusate by alumina chromatography. Most catechol-
amine metabolites do not bind to alumina. We checked for acidic
and glycol metabolites that might interfere with the measurement
of 3H-E and found none.
Plasma and urine E levels were measured by a sensitive
radioenzymatic assay [10]. Plasma and urine E samples were
extracted into a lipid solvent with a chelating agent to eliminate
calcium and other agents which interfere with catecholamine
assay in urine. The assay has a sensitivity of 6 pg/mI for E in
plasma. The coefficient of variation for measurement of E was
13% at the low levels found in plasma from resting subjects. Prior
studies have demonstrated identical assay efficiency in urine and
plasma [10].
Data analysis
We analyzed the decay of 3H-E in plasma using the model of
Bufano, Vaonag and Starcich [11] and Linares et al [12], who have
shown that 3H-NE kinetics followed a biexponential decay in
human plasma. We found that 3H-E kinetics fit well to the
biexponential decay equation:
3H-E = (A et) = (B e)
where A and B are constants and ci and /3 are the rate constants.
This equation describes the rate of decay of 3H-E in a two
compartment model. The volume of distribution of the first
compartment is then:
clearance
Volume =
a
and the half-life of 3H-E in the first compartment is:
a
The rate of decay of 3H-E was fitted to a biexponential decay
formula by the program R-STRIP (Micro Math Scientific Soft-
ware, Salt Lake City, UT, USA).
We used the following formulae to calculate 3H-E plasma and
urinary clearances:
3H-E clearance from plasma is calculated by:
3H-E inñised per minute
3H-E clearance =
plasma H-E
3H-E clearance to urine is calculated by the formula:
(3H-E m11) (ml urine min1)
urine clearance =
plasma H-E ml
If we assume that 3H-E and E are handled alike, then E should
be cleared from plasma into urine at the same rate as 3H-E. The
expected rate of appearance of E from plasma to urine can be
calculated as:
expected E in urine = 3H-Eurinaiy clearance plasma E
The percent of urinary E derived from the kidney was calculated
as:
Actual urine E - expected urine EPercent renal E = , 100Actual unne E
Statistical analysis
Data were analyzed by two-tailed t-test. Non-normally distrib-
uted data were analyzed by the Wilcoxon signed ranks test.
Repeatedly sampled data were analyzed by ANOVA for repeated
measures. Data are expressed as mean SEM.
Results
The 13 subjects were divided into two groups. The CON
subjects comprised S normal young men who were not obese and
who had normotensive blood pressures and normal lab chemis-
tries. The OHH subjects comprised 5 men nearly twice the age of
the CON group, who had significantly higher blood pressures, and
who were heavier than the men in the CON group. The two
groups had similar heart rates and serum creatinine levels (Table
1).
All subjects received a 3H-E infusion for three hours. Arterial
3H-E plasma levels remained stable during the final hour of the
infusion while urine and blood samples were collected. At the end
of three hours the 3H-E infusion was abruptly discontinued and
arterial plasma 3F1-E levels fell precipitously with a hiexponential
decay pattern (Fig. 1). Total body clearance of 3H-E from arterial
plasma was about 2,5 liter per minute in both groups of subjects.
After the 3H-E infusion was discontinued, the rapid decay half-life
of 3H-E in CON was 1.5 0.3 minutes, which did not differ from
the OHH half-life of 0.9 0.1 minute. The volume of distribution
for this rapid decay component of plasma 3H-E was 4.9 1.0 liter
for CON and 3.5 0.7 liter for OHH. Plasma 3H-E levels fell to
about ¼ of plateau 3l-l-E levels four minutes after termination of
the 3H-E infusion (Fig. 1).
Subjects had arterial blood sampled for endogenous E levels
four times during the final hour of 3H-E infusion and these
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Fig. 1. Levels of 3H-E in plasma from OHH and CON subjects. 3H-E was
infused for 180 minutes when the infusion was abruptly stopped and blood
sampled at 180 plus 0.5, 2, 4, 8 and 16 minutes. Levels of 3H-E did not
differ between OHH and CON by ANOVA for repeated measures.
samples were assayed in duplicate. The mean of these eight
plasma E level measurements for each subject ranged from 16 to
54 pg/mi. Plasma E levels were slightly higher in CON than in
OHH (Table 2) even though 3H-E clearance was similar in the
two groups. The amount of 3H-E excreted into urine was much
smaller than total body 3H-E disappearance. 3H-E clearance to
urine was about 170 mI/mm in both groups, a number which
approximates normal renal glomerular filtration rate. Making the
assumption that arterial E is handled by the kidney the same as
arterial 3H-E permits calculation of the amount of E that should
be excreted into urine from arterial blood. In CON this calculated
rate of 7471 865 pglml was significantly lower than the actual
excretion rate of 15,037 2625 pg/ml (P = 0.018 Wilcoxon). The
difference between predicted and measured excretion of arterial E
was even more extreme in OHH so that only 15% of urine E in
OHH was calculated to have come from arterial blood, signifi-
cantly less than actual urine E excretion (P = 0.029, Wilcoxon test,
Table 2). Although 3H-E clearance into urine was similar between
CON and OHH, plasma E levels were somewhat higher in CON
and urine E excretion was higher in OHH. As a consequence, a
greater fraction of urinary E was calculated to be derived from the
kidney in OI-IH than in CON.
Discussion
A major fraction of urinary E is derived from some source other
than the clearance of plasma E. Potential sources of this E in
urine are adrenal venous E, E previously taken up by the kidney
and excreted very slowly, or the synthesis of E by the kidney.
A very small fraction of urinary E is probably derived from E
taken up by the kidney and released later. The sympathetic nerves
have an active uptake process for norepinephrine and very small
amounts of E are taken up by active transport into noradrcncrgic
nerve terminals. We did not measure urine E until after two hours
of 3H-E infusion. E was cleared very quickly from the plasma hy
uptake-i and uptake-2 mechanisms and subsequent metabolism.
The precipitous decay of tracer levels of plasma 3l-l-E in this
experiment appeared to be quite similar to the decay of much
higher levels of infused E in a study by Clutter et al [31 During
the stimulation of cardiac sympathetic nerves in humans, the
amount of E released from sympathetic nerves ranged from
undetectable to 1.4% of the amount of norepinephrine released
[141. Following '4C-E injections, urinary 14C-E excretion in
women fell to trace levels by 20 minutes [15]. Thus, it is likely that
a very small amount of urinary E is derived from renal rioradren-
ergic nerves when the E is co-released with norepinephrine.
However, this amount of E is probably less than 2% of norepi-
nephrine levels, an amount too small to be detected under the
conditions of this experiment.
The kidney can synthesize E from the methylation of norepi-
nephrine and may be able to derive E from the action of sulfatase
on E-SO4. In humans, catecholamines can be inactivated by
sulfation to catecholamine sulfates. In the rat, dopamine sulfate
can be converted to a dopamine in the kidney by sulfatase. The
human kidney may be able to convert E-SO4 to E. In humans,
plasma dopamine sulfate and norepinephrine sulfate levels exceed
the levels of dopamine and of norepinephrine in plasma. Plasma
E-S04 levels are much lower than dopamine sulfate and norepi-
nephrine sulfate but similar to plasma E levels [16, 171. Plasma
levels of E-S04 could theoretically produce the amount of urine E
of renal origin found in this study if there were a high rate of
conversion of F-SO4 to E in human kidney.
The adrenal gland is located on top of the kidney. If blood from
the adrenal vein penetrated into the kidney it might be a source of
urinary E. However, the adrenal sits outside the renal capsule and
there are no known anatomic connections between the adrenal
veins and the renal parenchyma in humans. Urine is formed in the
renal glomerulus where pressures are higher than venous pres-
sure. It thus seems unlikely that adrenal venous E serves as a
direct source of urinary E for both anatomic and hydrostatic
reasons.
The renal synthesis of norepinephrine to E is a likely source of
some urinary E. Rat kidney can convert norepincphrine to urinary
E using two different N-methylating enzymes [4]. These enzymes
are present in human kidney in even higher levels [3]. These
methylating enzymes can use norepinephrine derived from nerve
endings or from the bloodstream as substrate. Buu et a! [5] have
also demonstrated that adrenalectomized rats can produce uri-
nary 3H-E from injected 3H-dopamine sulfate.
The adrenal medulla uses phenylethanolamine-N-methyltrans-
ferase (PNMT) to methylate norepinephrine into E. Since PNMT
is specific for -hydroxylated amines, it does not methylate
dopamine very well. The kidney contains both PNMT and an
N-methyltransferase which can methylate amines other than
norepinephrine so the kidney could methylate dopamine into
epinine, which could then be converted to E.
Although the source of excess urinary E is not known, intrare-
nal synthesis of F from E-S04 or from norepinephrine seem likely
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Table 2. E and 3H-E levels and clearance rates (mean SCM)
I,I,
0 120 140
CON OHH P<
Arterial E pg/ml
Arterial 3H-E clearance
43 4
2,495 123
27 3
2,669 180
0.05
NS
mI/mm
3H-E to urine clearance 174 13 172 24 NS
mI/mm
Predicted arterial to urine 7,471 865 4,692 980 NS
E pg/mm
Actual urine Epg/min 15,037 2625 39,783 12,991 0.05
% RenalE 43 9% 85 4% (LOl
160 180 196
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sources of urinary E of renal origin. E synthesized by the kidney
could potentially alter renal blood flow, sodium handling, and
renin release but the actual physiologic role of renally synthesized
E is not known.
Young riormotensive control subjects in this study derived 43%
of their urinary E from the kidney. A group of older, heavier
hypertensive men derived 85% of urinary E from the kidney. The
older group had both a higher level of renal E synthesis and lower
plasma E levels. Others have reported that plasma E levels are
lower in older subjects [18—21, reviewed in 22]. The older
hypertensive group not only had lower plasma E levels, they had
higher urinary E levels. Increased urinary E levels have been
found in some studies of hypertensives [23—25] but this is by no
means a uniform finding. The possibility of enhanced renal E
production in hypertensives is intriguing and deserves further
investigation.
E is present in human plasma and urine following bilateral
adrenalectomy [26] and a major fraction of human urinary E
comes from the kidney. Medline files from the past 10 years list
800 papers indexed under both "epinephrine" and "urine." A
great many of these papers used urinary E as a guide to
adrenomedullaty activity. E synthesized in the kidney is a major
source of urinary E and may heavily influence urinary E levels. E
stimulates renal renin release and sodium reabsorption, so human
renal E production may play a role in blood pressure regulation.
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